361 related articles for article (PubMed ID: 25242168)
21. 4'-hydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K/AKT signaling.
Sun D; Zhang F; Qian J; Shen W; Fan H; Tan J; Li L; Xu C; Yang Y; Cheng H
Chem Biol Interact; 2018 Dec; 296():26-33. PubMed ID: 30217479
[TBL] [Abstract][Full Text] [Related]
22. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Smith BD; Kaufman MD; Leary CB; Turner BA; Wise SC; Ahn YM; Booth RJ; Caldwell TM; Ensinger CL; Hood MM; Lu WP; Patt TW; Patt WC; Rutkoski TJ; Samarakoon T; Telikepalli H; Vogeti L; Vogeti S; Yates KM; Chun L; Stewart LJ; Clare M; Flynn DL
Mol Cancer Ther; 2015 Sep; 14(9):2023-34. PubMed ID: 26285778
[TBL] [Abstract][Full Text] [Related]
23. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
24. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
25. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
29. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
[TBL] [Abstract][Full Text] [Related]
31. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
32. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
[TBL] [Abstract][Full Text] [Related]
33. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
[TBL] [Abstract][Full Text] [Related]
34. Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2.
Dai G; Ding K; Cao Q; Xu T; He F; Liu S; Ju W
Eur J Pharmacol; 2019 Sep; 859():172525. PubMed ID: 31288005
[TBL] [Abstract][Full Text] [Related]
35. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
37. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
38. Novel Pyridine Bioisostere of Cabozantinib as a Potent
Karmacharya U; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575841
[TBL] [Abstract][Full Text] [Related]
39. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
E J; Xing J; Gong H; He J; Zhang W
Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
[TBL] [Abstract][Full Text] [Related]
40. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
